Table 3.
Correlation between SLCA4A expression and clinicopathological characteristics
| Total (N=97) | SLCA4A protein expression | P-value | ||
|---|---|---|---|---|
| Low expression (n=16) | High expression (n=81) | |||
| Age | ||||
| ≤ 65 | 43 (44.3%) | 4 (25.0%) | 39 (48.1%) | 0.090 |
| > 65 | 54 (55.7%) | 12 (72.0%) | 42 (41.9%) | |
| Gender | ||||
| Male | 53 (54.6%) | 11 (68.8%) | 42 (41.9%) | 0.219 |
| Female | 44 (45.4%) | 5 (31.2%) | 39 (48.1%) | |
| Pathology stage | ||||
| Ⅰ | 0 (0%) | 0 (0%) | 0 (0%) | 0.751 |
| Ⅱ | 51 (52.6%) | 9 (56.3%) | 42 (41.9%) | |
| Ⅲ | 46 (47.4%) | 7 (43.7%) | 39 (48.1%) | |
| Tumor size | ||||
| ≤ 5 cm | 50 (51.5%) | 10 (62.5%) | 40 (49.4%) | 0.343 |
| >5 cm | 47 (48.5%) | 6 (37.5%) | 41 (50.6%) | |
| T stage | ||||
| T1 | 1 (1.0%) | 0 (0%) | 1 (1.2%) | 0.852 |
| T2 | 5 (5.2%) | 0 (0%) | 5 (6.2%) | |
| T3 | 74 (76.3%) | 14 (87.5%) | 60 (74.1%) | |
| T4 | 17 (17.5%) | 2 (12.5%) | 15 (18.5%) | |
| N stage | ||||
| N0 | 57 (58.8%) | 9 (56.3%) | 48 (59.3%) | 0.872 |
| N1 | 29 (29.9%) | 6 (37.5%) | 23 (28.4%) | |
| N2 | 11 (11.3%) | 1 (6.2%) | 10 (12.3%) | |
| M stage | ||||
| M0 | 94 (96.9%) | 15 (93.8%) | 79 (97.5%) | 0.430 |
| M1 | 3 (3.1%) | 1 (6.2%) | 2 (2.5%) | |